BiomX Inc. (PHGE) 10-Year Financial Performance & Capital Metrics

PHGE • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Show more

Revenue $0
EBITDA -$37M -38.8%
Net Income -$18M +32.3%
EPS (Diluted) -1.47 +71.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -130.21% +40.0%
ROIC -305.15% +9.4%
Debt/Equity 0.40 -91.9%
Interest Coverage -14.01 -21.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 1420.0x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-181.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM96.49%

ROCE

10Y Avg-69.31%

5Y Avg-82.93%

3Y Avg-106.53%

Latest-159.88%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	95K	210K	0	0	0	0	871K	1.8M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-95K	-210K	0	0	0	0	-871K	-1.8M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.21%	1%	-	-	-	-	-1.07%
Operating Expenses+	7.28M	12.93M	22.21M	30.26M	35.46M	27.22M	26.81M	37.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.54M	3.36M	8.72M	9.99M	11.27M	9.46M	7.78M	11.78M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	4.74M	9.57M	13.96M	21.61M	22.68M	16.24M	19.04M	24.66M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-466K	-1.34M	1.52M	1.52M	0	785K
Operating Income+	-7.37M	-13.14M	-22.21M	-30.26M	-35.46M	-27.22M	-27.68M	-39.03M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.78%	-0.69%	-0.36%	-0.17%	0.23%	-0.02%	-0.41%
EBITDA+	-7.28M	-12.93M	-21.89M	-29.6M	-32.9M	-24.7M	-26.81M	-37.22M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.78%	-0.69%	-0.35%	-0.11%	0.25%	-0.09%	-0.39%
D&A (Non-Cash Add-back)	95K	210K	318K	662K	2.56M	2.52M	871K	1.8M
EBIT	-6.43M	-12.72M	-22.21M	-30.26M	-35.46M	-26.18M	-23.69M	-14.93M
Net Interest Income+	0	0	857K	634K	-697K	-1.17M	-1.28M	-1.74M
Interest Income	-21K	0	921K	641K	2K	902K	1.12M	1.05M
Interest Expense	0	0	64K	7K	699K	2.07M	2.4M	2.79M
Other Income/Expense	939K	421K	1.64M	172K	-697K	-1.03M	1.54M	21.31M
Pretax Income+	-6.43M	-12.72M	-20.56M	-30.09M	-36.16M	-28.25M	-26.15M	-17.71M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	67K	65K	23K	13K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.98%	-0.62%	-0.46%	-0.2%	0.22%	0.08%	0.32%
Net Income (Continuing)	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.27	-6.46	-0.84	-1.30	-13.93	-9.49	-5.10	-1.47
EPS Growth %	-	-0.98%	0.87%	-0.55%	-9.72%	0.32%	0.46%	0.71%
EPS (Basic)	-3.27	-6.46	-0.84	-1.30	-13.93	-9.49	-5.10	-1.47
Diluted Shares Outstanding	19.68M	20.02M	22.63M	23.06M	26.01M	29.85M	51.33M	13.14B
Basic Shares Outstanding	19.68M	20.02M	22.63M	23.06M	26.01M	29.85M	51.33M	69.81M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.47M	39.89M	84.53M	60.67M	66.64M	36.88M	17.63M	20.52M
Cash & Short-Term Investments	8.15M	39.66M	82.41M	56.33M	62.1M	33.33M	14.91M	17.81M
Cash Only	6.99M	8.6M	72.41M	36.48M	62.1M	31.33M	14.91M	17.81M
Short-Term Investments	1.15M	31.05M	10M	19.85M	0	2M	0	0
Accounts Receivable	0	0	244K	0	888K	567K	574K	1.17M
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	-29K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	50K	2.25M	1.4M	1.49M	1.52M	254K
Total Non-Current Assets+	5.52M	5.44M	7.59M	9.7M	11.35M	8.65M	7.4M	22.71M
Property, Plant & Equipment	960K	887K	3.03M	6.66M	9.83M	8.65M	7.4M	10.5M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	4.56M	4.56M	3.04M	1.52M	0	0	12.05M
Long-Term Investments	0	70.88M	0	0	0	0	0	161K
Other Non-Current Assets	4.56M	-70.88M	5K	0	0	0	0	0
Total Assets+	13.99M	45.33M	92.12M	70.36M	77.99M	45.53M	25.03M	43.23M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	2.24%	1.03%	-0.24%	0.11%	-0.42%	-0.45%	0.73%
Total Current Liabilities+	1.46M	1.64M	6.22M	7.16M	11.04M	7.94M	11.18M	8.27M
Accounts Payable	1K	56.58K	3.25M	2.32M	2.79M	820K	1.38M	1.88M
Days Payables Outstanding	3.84	98.34	-	-	-	-	578.72	380.99
Short-Term Debt	40K	0	375K	0	0	4.28M	5.79M	0
Deferred Revenue (Current)	-40K	58K	60K	65K	1000K	242K	28K	0
Other Current Liabilities	1.42M	581K	756K	0	0	0	-28K	1.48M
Current Ratio	5.81x	24.34x	13.58x	8.47x	6.03x	4.65x	1.58x	2.48x
Quick Ratio	5.81x	24.35x	13.58x	8.47x	6.03x	4.65x	1.58x	2.48x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1M	889K	1.44M	5.73M	19.41M	16.55M	10.77M	10.82M
Long-Term Debt	0	0	0	0	14.41M	10.59M	5.4M	0
Capital Lease Obligations	0	0	856K	5.03M	4.79M	3.8M	3.24M	8.45M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1M	889K	585K	701K	215K	188K	155K	2.36M
Total Liabilities	2.46M	2.53M	7.67M	12.89M	30.45M	24.49M	21.95M	19.09M
Total Debt+	40K	0	1.23M	5.89M	20.02M	19.36M	15.09M	9.58M
Net Debt	-6.95M	-8.6M	-71.18M	-30.58M	-42.08M	-11.97M	185K	-8.23M
Debt / Equity	0.00x	-	0.01x	0.10x	0.42x	0.92x	4.90x	0.40x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-346.98x	-4322.57x	-50.73x	-13.16x	-11.52x	-14.01x
Total Equity+	11.53M	42.8M	84.46M	57.47M	47.53M	21.04M	3.08M	24.15M
Equity Growth %	-	2.71%	0.97%	-0.32%	-0.17%	-0.56%	-0.85%	6.84%
Book Value per Share	0.59	2.14	3.73	2.49	1.83	0.70	0.06	0.00
Total Shareholders' Equity	11.53M	42.8M	84.46M	57.47M	47.53M	21.04M	3.08M	24.15M
Common Stock	201	65.75M	2K	2K	2K	2K	3K	6K
Retained Earnings	-8.89M	-21.61M	-42.17M	-72.26M	-108.48M	-136.8M	-162.97M	-180.7M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.02K	-21.61M	0	-72.26M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.1M	-11.3M	-17.58M	-24.45M	-27.57M	-29.09M	-21.29M	-36.98M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.76%	-0.55%	-0.39%	-0.13%	-0.06%	0.27%	-0.74%
Net Income	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Depreciation & Amortization	95K	210K	318K	2.18M	2.56M	2.52M	871K	1.8M
Stock-Based Compensation	0	0	938K	2.89M	3.24M	1.53M	1.06M	1.85M
Deferred Taxes	0	-1.22K	0	0	24K	0	0	0
Other Non-Cash Items	1.32M	-112K	-304K	116K	-276K	-396K	477K	-19.91M
Working Capital Changes	928K	367K	2.03M	453K	3.1M	-4.43M	2.48M	-2.99M
Change in Receivables	-225K	187K	-100K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	407K	-228K	3.06M	-858K	427K	-1.98M	556K	-3.17M
Cash from Investing+	-2.12M	-30.04M	19.74M	-10.86M	16.17M	-2.11M	1.95M	715K
Capital Expenditures	-850K	-137K	-1.31M	-1.01M	-3.68M	-112K	-50K	-30K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-29.9M	21.05M	0	4K	5K	1K	82K
Cash from Financing+	12.95M	43.04M	61.55M	134K	37.28M	292K	2.9M	38.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	57.97M	232K	130K	19K	-333K	27.83M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.95M	-11.44M	-18.89M	-25.46M	-31.25M	-29.2M	-21.34M	-37.01M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.31%	-0.65%	-0.35%	-0.23%	0.07%	0.27%	-0.73%
FCF per Share	-0.25	-0.57	-0.83	-1.10	-1.20	-0.98	-0.42	-0.00
FCF Conversion (FCF/Net Income)	0.64x	0.89x	0.85x	0.81x	0.76x	1.03x	0.81x	2.09x
Interest Paid	0	0	0	0	67K	1.55M	1.87M	1.44M
Taxes Paid	0	0	0	0	399K	65K	54K	13K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55.79%	-46.82%	-32.32%	-42.4%	-69%	-82.59%	-216.99%	-130.21%
Return on Invested Capital (ROIC)	-	-50.83%	-70.16%	-113%	-164.49%	-281.25%	-336.77%	-305.15%
Debt / Equity	0.00x	-	0.01x	0.10x	0.42x	0.92x	4.90x	0.40x
Interest Coverage	-	-	-346.98x	-4322.57x	-50.73x	-13.16x	-11.52x	-14.01x
FCF Conversion	0.64x	0.89x	0.85x	0.81x	0.76x	1.03x	0.81x	2.09x

Frequently Asked Questions

Growth & Financials

BiomX Inc. (PHGE) grew revenue by 0.0% over the past year. Growth has been modest.

BiomX Inc. (PHGE) reported a net loss of $37.4M for fiscal year 2024.

Dividend & Returns

BiomX Inc. (PHGE) has a return on equity (ROE) of -130.2%. Negative ROE indicates the company is unprofitable.

BiomX Inc. (PHGE) had negative free cash flow of $28.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

BiomX Inc. (PHGE) 10-Year Financial Performance & Capital Metrics

PHGE • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

Revenue $0
EBITDA -$37M -38.8%
Net Income -$18M +32.3%
EPS (Diluted) -1.47 +71.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -130.21% +40.0%
ROIC -305.15% +9.4%
Debt/Equity 0.40 -91.9%
Interest Coverage -14.01 -21.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 1420.0x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-181.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM96.49%

ROCE

10Y Avg-69.31%

5Y Avg-82.93%

3Y Avg-106.53%

Latest-159.88%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	95K	210K	0	0	0	0	871K	1.8M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-95K	-210K	0	0	0	0	-871K	-1.8M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.21%	1%	-	-	-	-	-1.07%
Operating Expenses+	7.28M	12.93M	22.21M	30.26M	35.46M	27.22M	26.81M	37.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.54M	3.36M	8.72M	9.99M	11.27M	9.46M	7.78M	11.78M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	4.74M	9.57M	13.96M	21.61M	22.68M	16.24M	19.04M	24.66M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-466K	-1.34M	1.52M	1.52M	0	785K
Operating Income+	-7.37M	-13.14M	-22.21M	-30.26M	-35.46M	-27.22M	-27.68M	-39.03M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.78%	-0.69%	-0.36%	-0.17%	0.23%	-0.02%	-0.41%
EBITDA+	-7.28M	-12.93M	-21.89M	-29.6M	-32.9M	-24.7M	-26.81M	-37.22M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.78%	-0.69%	-0.35%	-0.11%	0.25%	-0.09%	-0.39%
D&A (Non-Cash Add-back)	95K	210K	318K	662K	2.56M	2.52M	871K	1.8M
EBIT	-6.43M	-12.72M	-22.21M	-30.26M	-35.46M	-26.18M	-23.69M	-14.93M
Net Interest Income+	0	0	857K	634K	-697K	-1.17M	-1.28M	-1.74M
Interest Income	-21K	0	921K	641K	2K	902K	1.12M	1.05M
Interest Expense	0	0	64K	7K	699K	2.07M	2.4M	2.79M
Other Income/Expense	939K	421K	1.64M	172K	-697K	-1.03M	1.54M	21.31M
Pretax Income+	-6.43M	-12.72M	-20.56M	-30.09M	-36.16M	-28.25M	-26.15M	-17.71M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	67K	65K	23K	13K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.98%	-0.62%	-0.46%	-0.2%	0.22%	0.08%	0.32%
Net Income (Continuing)	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.27	-6.46	-0.84	-1.30	-13.93	-9.49	-5.10	-1.47
EPS Growth %	-	-0.98%	0.87%	-0.55%	-9.72%	0.32%	0.46%	0.71%
EPS (Basic)	-3.27	-6.46	-0.84	-1.30	-13.93	-9.49	-5.10	-1.47
Diluted Shares Outstanding	19.68M	20.02M	22.63M	23.06M	26.01M	29.85M	51.33M	13.14B
Basic Shares Outstanding	19.68M	20.02M	22.63M	23.06M	26.01M	29.85M	51.33M	69.81M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.47M	39.89M	84.53M	60.67M	66.64M	36.88M	17.63M	20.52M
Cash & Short-Term Investments	8.15M	39.66M	82.41M	56.33M	62.1M	33.33M	14.91M	17.81M
Cash Only	6.99M	8.6M	72.41M	36.48M	62.1M	31.33M	14.91M	17.81M
Short-Term Investments	1.15M	31.05M	10M	19.85M	0	2M	0	0
Accounts Receivable	0	0	244K	0	888K	567K	574K	1.17M
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	-29K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	50K	2.25M	1.4M	1.49M	1.52M	254K
Total Non-Current Assets+	5.52M	5.44M	7.59M	9.7M	11.35M	8.65M	7.4M	22.71M
Property, Plant & Equipment	960K	887K	3.03M	6.66M	9.83M	8.65M	7.4M	10.5M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	4.56M	4.56M	3.04M	1.52M	0	0	12.05M
Long-Term Investments	0	70.88M	0	0	0	0	0	161K
Other Non-Current Assets	4.56M	-70.88M	5K	0	0	0	0	0
Total Assets+	13.99M	45.33M	92.12M	70.36M	77.99M	45.53M	25.03M	43.23M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	2.24%	1.03%	-0.24%	0.11%	-0.42%	-0.45%	0.73%
Total Current Liabilities+	1.46M	1.64M	6.22M	7.16M	11.04M	7.94M	11.18M	8.27M
Accounts Payable	1K	56.58K	3.25M	2.32M	2.79M	820K	1.38M	1.88M
Days Payables Outstanding	3.84	98.34	-	-	-	-	578.72	380.99
Short-Term Debt	40K	0	375K	0	0	4.28M	5.79M	0
Deferred Revenue (Current)	-40K	58K	60K	65K	1000K	242K	28K	0
Other Current Liabilities	1.42M	581K	756K	0	0	0	-28K	1.48M
Current Ratio	5.81x	24.34x	13.58x	8.47x	6.03x	4.65x	1.58x	2.48x
Quick Ratio	5.81x	24.35x	13.58x	8.47x	6.03x	4.65x	1.58x	2.48x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1M	889K	1.44M	5.73M	19.41M	16.55M	10.77M	10.82M
Long-Term Debt	0	0	0	0	14.41M	10.59M	5.4M	0
Capital Lease Obligations	0	0	856K	5.03M	4.79M	3.8M	3.24M	8.45M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1M	889K	585K	701K	215K	188K	155K	2.36M
Total Liabilities	2.46M	2.53M	7.67M	12.89M	30.45M	24.49M	21.95M	19.09M
Total Debt+	40K	0	1.23M	5.89M	20.02M	19.36M	15.09M	9.58M
Net Debt	-6.95M	-8.6M	-71.18M	-30.58M	-42.08M	-11.97M	185K	-8.23M
Debt / Equity	0.00x	-	0.01x	0.10x	0.42x	0.92x	4.90x	0.40x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-346.98x	-4322.57x	-50.73x	-13.16x	-11.52x	-14.01x
Total Equity+	11.53M	42.8M	84.46M	57.47M	47.53M	21.04M	3.08M	24.15M
Equity Growth %	-	2.71%	0.97%	-0.32%	-0.17%	-0.56%	-0.85%	6.84%
Book Value per Share	0.59	2.14	3.73	2.49	1.83	0.70	0.06	0.00
Total Shareholders' Equity	11.53M	42.8M	84.46M	57.47M	47.53M	21.04M	3.08M	24.15M
Common Stock	201	65.75M	2K	2K	2K	2K	3K	6K
Retained Earnings	-8.89M	-21.61M	-42.17M	-72.26M	-108.48M	-136.8M	-162.97M	-180.7M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.02K	-21.61M	0	-72.26M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.1M	-11.3M	-17.58M	-24.45M	-27.57M	-29.09M	-21.29M	-36.98M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.76%	-0.55%	-0.39%	-0.13%	-0.06%	0.27%	-0.74%
Net Income	-6.43M	-12.72M	-20.56M	-30.09M	-36.23M	-28.32M	-26.17M	-17.73M
Depreciation & Amortization	95K	210K	318K	2.18M	2.56M	2.52M	871K	1.8M
Stock-Based Compensation	0	0	938K	2.89M	3.24M	1.53M	1.06M	1.85M
Deferred Taxes	0	-1.22K	0	0	24K	0	0	0
Other Non-Cash Items	1.32M	-112K	-304K	116K	-276K	-396K	477K	-19.91M
Working Capital Changes	928K	367K	2.03M	453K	3.1M	-4.43M	2.48M	-2.99M
Change in Receivables	-225K	187K	-100K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	407K	-228K	3.06M	-858K	427K	-1.98M	556K	-3.17M
Cash from Investing+	-2.12M	-30.04M	19.74M	-10.86M	16.17M	-2.11M	1.95M	715K
Capital Expenditures	-850K	-137K	-1.31M	-1.01M	-3.68M	-112K	-50K	-30K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-29.9M	21.05M	0	4K	5K	1K	82K
Cash from Financing+	12.95M	43.04M	61.55M	134K	37.28M	292K	2.9M	38.37M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	57.97M	232K	130K	19K	-333K	27.83M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.95M	-11.44M	-18.89M	-25.46M	-31.25M	-29.2M	-21.34M	-37.01M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.31%	-0.65%	-0.35%	-0.23%	0.07%	0.27%	-0.73%
FCF per Share	-0.25	-0.57	-0.83	-1.10	-1.20	-0.98	-0.42	-0.00
FCF Conversion (FCF/Net Income)	0.64x	0.89x	0.85x	0.81x	0.76x	1.03x	0.81x	2.09x
Interest Paid	0	0	0	0	67K	1.55M	1.87M	1.44M
Taxes Paid	0	0	0	0	399K	65K	54K	13K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55.79%	-46.82%	-32.32%	-42.4%	-69%	-82.59%	-216.99%	-130.21%
Return on Invested Capital (ROIC)	-	-50.83%	-70.16%	-113%	-164.49%	-281.25%	-336.77%	-305.15%
Debt / Equity	0.00x	-	0.01x	0.10x	0.42x	0.92x	4.90x	0.40x
Interest Coverage	-	-	-346.98x	-4322.57x	-50.73x	-13.16x	-11.52x	-14.01x
FCF Conversion	0.64x	0.89x	0.85x	0.81x	0.76x	1.03x	0.81x	2.09x

Frequently Asked Questions

Growth & Financials

BiomX Inc. (PHGE) grew revenue by 0.0% over the past year. Growth has been modest.

BiomX Inc. (PHGE) reported a net loss of $37.4M for fiscal year 2024.

Dividend & Returns

BiomX Inc. (PHGE) has a return on equity (ROE) of -130.2%. Negative ROE indicates the company is unprofitable.

BiomX Inc. (PHGE) had negative free cash flow of $28.3M in fiscal year 2024, likely due to heavy capital investments.